![](https://www.worldpharmatoday.com/images/nBanners/Docuvera-728x90.jpeg")
Real World Evidence is at the root of an ongoing and critical transformation in medical care. By incorporating data from the real-world into their development programs, drug developers are more than ever now able to drive more patient-facing outcomes, by supporting it with effective evidence-based decision-making across the product life cycle.
Our mission for the 7th IMPACCT: Real World Evidence meeting is simple: Build a collaborative forum that unites forward thinking industry leaders and innovators active in the RWE space for a comprehensive and open discussion on how to support and advance the generation and utilization of RWE across drug life cycle, from clinical R&D to commercialization.
Just some of our expert speakers already confirmed include:
- Tony Hebden, VP, HEOR, AbbVie
- Javier Jimenez, VP & Global Head of RWE & Clinical Outcomes, Sanofi
- Danny Wiederkehr, Senior Director, Global HEOR Team, Pfizer
- Sebastian Schneeweiss, Professor of Medicine & Epidemiology, Harvard Medical School
- Melvin Olson, Global Head of RWD Strategy & Innovation, Novartis
- Cathy Critchlow, VP, Center for Observational Research, Amgen
- Keith Friend, Global Medical Director, Cardiovascular, Bristol-Myers Squibb
- Mandeep Kaur, VP & Head of North America Medical Affairs for Immunology, Sanofi
- John Graham, SVP, Medical Engagement & Value Evidence & Outcomes, GlaxoSmithKline
- Michael Lees, Head of Value, Evidence & Portfolio, Takeda
Join the discussion alongside 80+ highly focused peers and leaders for exclusive insights that will inspire you to successfully drive patient-facing innovation across the product life-cycle.
Click here to see the full program and speaker line-up: http://bit.ly/2JeR4DE
We hope you can join us.
World Pharma Today readers receive an exclusive 10% discount to attend the forum. Simply quote VIP Code WPTPR10 at checkout to receive your discount.
We hope you’ll be able to join us.
The IMPACCT: Real World Evidence Team
